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PCa detection was assessed by multivariate logistic regres-
sion analysis (MLRA).  Results: 392 evaluable questionnaires 
were collected (return rate 65%). 81% of the physicians de-
clared that they apply PSA testing for early PCa detection; of 
these, 58 and 15% would screen patients until the age of 80 
and 90 years, respectively. In case of a pathological PSA level, 
77% would immediately refer the patient to a urologist, while 
13% would re-assess elevated PSA levels after 3–12 months. 
Based on MLRA, the following criteria were independently 
associated with a positive attitude towards PSA-based early 
PCa detection: specialisation (application of early detection 
more frequent for GPs and hospital-based ISs) (OR 3.12; p < 
0.001), physicians who use exclusively GP or IS education (OR 
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 Abstract 
 Objectives: The aim of this cross-sectional study was to eval-
uate the value of prostate-specific antigen (PSA) testing as a 
tool for early detection of prostate cancer (PCa) applied by 
general practitioners (GPs) and internal specialists (ISs) as 
well as to assess criteria leading to the application of PSA-
based early PCa detection.  Methods: Between May and 
 December 2012, a questionnaire containing 16 items was 
sent to 600 GPs and ISs in the federal state Brandenburg and 
in Berlin (Germany). The independent influence of several cri-
teria on the decision of GPs and ISs to apply PSA-based early 
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3.95; p = 0.002), and physicians who recommend yearly PSA 
assessment after the age of 50 (OR 6.85; p < 0.001).  Conclu-
sions: GPs and ISs frequently apply PSA-based early PCa de-
tection. In doing so, 13% would initiate specific referral to a 
urologist in case of pathological PSA values too late. Im-
provement of this situation could possibly result from spe-
cific educational activities for non-urological physicians ac-
tive in fields of urological core capabilities, which should be 
guided by joint boards of the national associations of urology 
and general medicine.  © 2014 S. Karger AG, Basel 
 Introduction 
 According to the German interdisciplinary Guideline for 
Prevention, Diagnostics and Treatment for different stages 
of prostate cancer (PCa), an early detection of PCa can be 
offered to asymptomatic men starting at the age of 40 if their 
life expectancy is assumed to exceed 10 years  [1] . Detailed 
counselling of patients about potential consequences is 
mandatory before any method of early detection is per-
formed. After informed consent, the early detection ap-
proach should consist of measurement of prostate-specific 
antigen (PSA) and digital rectal examination of the prostate 
 [1] . An indication for a standardised multicore prostate bi-
opsy is given when one of the following criteria is met: (a) 
controlled PSA  ≥ 4 ng/ml, (b) a digital rectal examination 
suspicious for PCa or (c) a suspect rise in PSA levels  [1] .
 The impact of a population-based PSA screening for 
PCa is still under debate after results of two large ran-
domised controlled studies have been published: the 
 European Randomized Study of Screening for Prostate 
Cancer (ERSPC)  [2] and the Prostate, Lung, Colorectal and 
Ovarian (PLCO) trial  [3] . This has led to inconsistent rec-
ommendations in various international guidelines. The 
U.S. Preventive Services Task Force (USPSTF) argues 
against PSA-based early PCa detection, while the American 
Urological Association (AUA), the European Association of 
Urology (EAU) and the German interdisciplinary S3 guide-
line recommend that men be thoroughly informed about 
advantages and disadvantages as well as potential conse-
quences prior to PSA-based early PCa detection  [1, 4–6] .
 No data are available on how guideline recommenda-
tions concerning PSA-based early PCa detection are ap-
plied in daily routine in Germany. Optimally, urologists’ 
diagnostic approaches should be consistent with German 
interdisciplinary guidelines and the recently published 
results of the ERSPC and the PLCO trial. On the other 
hand, it has to be assumed that most men will initially 
contact their general practitioner (GP) or internal spe-
cialist (IS) for early detection of PCa  [7–10] . Evidence is 
lacking about the proportion of population-based PCa 
screening initiated by GPs and ISs. In addition, there are 
no data on which criteria influence early detection strate-
gies applied by GPs and ISs  [11, 12] .
 The aim of this cross-sectional study was to evaluate 
the value of PSA testing as a tool for early detection of PCa 
applied by GPs and ISs as well as to assess criteria leading 
to the application of PSA-based early PCa detection.
 Materials and Methods 
 Questionnaire 
 A questionnaire containing 16 items was designed ( table 1 ) and 
sent to GPs and ISs. Participants were asked about their specialist 
medical training, sources used for continuing education concerning 
PSA testing, and their personal approach to PSA testing for early 
detection of PCa. It was also assessed how GPs and ISs judge existing 
evidence for the reduction of PCa-specific mortality by early detec-
tion based on PSA testing. In addition, physicians were requested to 
recommend a treatment option for a 62-year-old, otherwise healthy 
patient with newly diagnosed low-risk PCa. Finally, GPs and ISs 
were asked whether they would consider the status of a clinic as a 
certified PCa centre as opposed to non-certified centres when ad-
mitting their PCa patients to hospital for initiation of treatment.
 Workflow 
 The questionnaire was sent to GPs and ISs in different parts of 
the federal state of Brandenburg and in Berlin between May and 
December 2012 – a sufficient period of time after the updated 
 German S3 guideline for early detection, diagnosis and treatment 
of PCa  [1] as well as updated results of the two large international 
studies on PSA-based screening (ERSPC in March 2012  [2] and 
PLCO in January 2012  [3] ) were published. All office-based GPs 
and ISs in the following districts in Brandenburg were contacted: 
Cottbus (54 GPs and 45 ISs), Ostprignitz-Ruppin (47 GPs and 21 
ISs), Spree-Neiße (44 GPs and 21 ISs), Oder-Spree (77 GPs and 33 
ISs), and Havelland (50 GPs and 28 ISs). In addition, all 133 office-
based GPs affiliated with the Charité – University Hospital in 
 Berlin were provided with a questionnaire, resulting in a total 
number of 533 office-based physicians. As a major part of medical 
training for GPs is done in internal medicine departments, the 
questionnaire was also sent to 67 hospital-based ISs in Neuruppin 
(50) and Nauen (17). Hence, a total of 600 GPs and ISs were asked 
to fill in the questionnaire.
 As the answers were provided in an anonymised fashion, all 
participants could only be contacted once. All completed ques-
tionnaires received until March 1, 2013 were centrally scanned by 
a high-performance scanner in St. Elisabeth-Klinikum Straubing. 
The data were then separately tested for plausibility by two authors 
(A.M.A., O.M.). Data sets that were inaccurately or incompletely 
assessed were corrected by those two authors whenever unequivo-
cally possible, based on the corresponding questionnaire. The 
study was approved by the local ethical review board (ERB ap-
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Table 1.  Questionnaire comprising 16 items sent to GPs and ISs in the federal state of Brandenburg and in Berlin from May to 
 December 2012
1. Which specialisation do you have, are you board-certified or do you work in a clinic?
◻ General practitioner (board-certified, office-based)
◻ Internal specialist (board-certified or resident, office-based)
◻ General practitioner (non-certified)
◻ Combination of specialisations in the office-based sector
◻ Internal specialist (board-certified or resident, working in hospitals)
2. When did you complete your specialisation?
◻ 0–5 years ago
◻ 6–10 years ago
◻ 11–20 years ago
◻ 21–30 years ago
◻ >30 years ago
3. Do you use the prostate-specific antigen (PSA) assessment as a screening instrument for detection of PCa?
◻ Yes
◻ No





◻ Not at all
◻ I cannot answer this question
5. Up to which age would you recommend PSA assessment for an asymptomatic man?
◻ Up to 60 years
◻ Up to 70 years
◻ Up to 80 years
◻ Up to 90 years
◻ Not at all
◻ I cannot answer this question




◻ PSA cut-off adjusted to patient’s age
◻ PSA cut-off adjusted to digital rectal examination and free PSA
◻ I cannot answer this question
7. What is your further management after detecting an increased PSA level according to your own definition in an asymptomatic 
man?
◻ Immediate PSA monitoring after 2–4 weeks
◻ Empirical antibiotic therapy, then PSA re-assessment (after 2–4 weeks)
◻ PSA assessment after 3–6 months
◻ PSA assessment after 7–12 months
◻ Urine culture or culture of prostate expressate
◻ Referral to a board-certified urologist
◻ I cannot answer this question
8. Having decided for PSA monitoring (see question 7) and having received a non-pathological result: What would you do further on?
◻ Immediate PSA re-assessment after 2–4 weeks
◻ PSA assessment after 3–6 months
◻ PSA assessment after 7–12 months
◻ Referral to a board-certified urologist
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Table 1.  (continued)
9. Having decided for PSA monitoring (see question 7) and having received another pathological result: What would you do further 
on?
◻ Immediate PSA re-assessment after 2–4 weeks
◻ Empirical antibiotic therapy, then PSA re-assessment
◻ PSA assessment after 3–6 months
◻ PSA assessment after 7–12 months
◻ Urine culture or culture of prostate expressate
◻ Referral to a board-certified urologist
◻ I cannot answer this question




◻ No administration of antibiotics
◻ I cannot answer this question
11. Do you consider a decrease of PCa mortality by PSA-based screening possible?
◻ Yes, as proven by evidence
◻ No, as proven by evidence
◻ I cannot answer this question
◻ A decrease of PCa mortality by PSA-based screening is possible, but more robust data are needed
12. Which of the following treatment strategies would you recommend for a 62-year-old man without any comorbidities diagnosed 
with a low-risk PCa (verified by biopsy)?
◻ Prostatectomy (open surgery)
◻ Prostatectomy (laparoscopic, robot-assisted)
◻ Prostatectomy (laparoscopic, extraperitoneal or intraperitoneal)
◻ Modern type of percutaneous radiotherapy (e.g. IMRT)
◻ Brachytherapy
◻ Active surveillance including PSA monitoring and repeated biopsies
◻ I cannot answer this question




◻ I cannot answer this question
◻ At first, yes, but further re-assessment intervals should be adjusted to PSA levels
14. What kind of sources for knowledge acquisition do you use concerning the indication for PSA-based screening?
◻ Study of literature/guidelines
◻ GP/IS training (conventions, meetings, round tables)
◻ Urological training (e.g. in certified PCa centres)
◻ Personal contact with urologists
◻ Numerous of given options
◻ None of given options
15. Do you consider that the aptitude of a clinic as a certified PCa centre goes along with a higher quality of treatment?
◻ Yes
◻ No, on the contrary
◻ I cannot answer this question
◻ No, not automatically, but treatment outcome reporting is more transparent
16. Would you recommend your patients being treated in a PCa centre, rather than in a clinic without certification?
◻ Yes
◻ No, on the contrary
◻ Recommendation irrespective of status as PCa centre, status and regional reputation of the clinic in question and of its per-
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 Statistical Analysis 
 The results of nominal scaled items were analysed descriptive-
ly. The primary objective and distinguishing feature was the reply 
to question 1.3: ‘Do GPs or ISs use PSA testing as an instrument 
for early detection of PCa?’ ( table 1 ). Bivariate correlations were 
calculated between item 1.3 and diverse other items (see below) 
which had been dichotomised before. The Kendall (τ) correlation 
coefficient constitutes a dimensionless number with a range be-
tween –1 and 1. Taking into account the orientation of the corre-
lating items, τ shows a negative (τ < 0) or a positive (τ > 0) correla-
tion, respectively. Moreover, different distributions of dichot-
omised response options of selected items on the two options of 
item 1.3 were tested by using Fisher’s exact test.
 Finally, a multivariate logistic regression analysis (MLRA) was 
created to test the independent impact of different criteria on the 
decision of GPs and ISs to use PSA as an instrument for early de-
tection (item 1.3 serving as dependent variable). Different re-
sponse options of the items, which were included into the MLRA, 
were combined as far as it made sense with regard to contents and 
if they showed a reasonable percentage allocated to item 1.3. Thus, 
it was possible to include independent items regularly dichot-
omised to the MLRA. The quality of adaption of the MLRA was 
checked by the likelihood function. In contrast, the coefficient of 
determination R 2 by Nagelkerke shows the proportion of the vari-
ance which is explained by logistic regression (ideal: R 2  = 1, con-
sistent with 100%). In other words, the coefficient of determina-
tion acts as a surrogate how fit the MLRA is. When generating the 
MLRA, a R 2  ≥ 0.35 was requested. The impact of different indepen-
dent variables on the dependent variable is shown by the OR in-
cluding a 95% confidence interval. The internal validity of the sin-
gle variables (indicator items) in the MLRA was analysed by using 
the bootstrap technique (based on 1,000 random samples). The 
detected difference of the final coefficient of regression was calcu-
lated as slope index (reduction index) and represents the extent of 
overestimation. In general, the slope index varied from 0 to 1, while 
a slope index of 1 excludes an overestimation.
 Data analysis was performed using SPSS 20 (IBM Corporation 
2011). All p values mentioned in this article are two-sided. The 
significance level was considered statistically significant for all tests 
if p was  ≤ 0.05.
 Results 
 In total, 65.3% (392/600) of questionnaires were re-
turned. Return rates differed between the three groups of 
physicians. GPs, office-based ISs and ISs working in hos-
pitals responded in 73% (282/385), 53% (78/148) and 48% 
(32/67), respectively.
 Descriptive statistics are shown in  table 2 . All items are 
linked with the corresponding questions of the question-
naire ( table 1 ). PSA testing for early detection of PCa is 
applied by 81% of physicians. Among physicians who 
specified an age limit at which they stop PSA-based early 
PCa detection, 58.3 and 15% stop PSA measurements at 
a patient age of 80 and 90 years, respectively. In total, 331 
defined a given cut-off level for PSA testing. Of those, 
49.5% mentioned a cut-off level of 4 ng/ml, which is con-
sistent with the German S3 guideline; 17.2% preferred 
age-adjusted cut-off levels.
 In case of a pathological PSA level, 76.6% of the col-
leagues would decide to immediately refer the patient to a 
board-certified urologist, while 12.5% answering this 
question stated that they would re-assess PSA levels after 
an interval of 3–12 months themselves. In case of a normal 
control after an initially pathological PSA level, 39.4% of 
the colleagues answering this topic would perform anoth-
er PSA test after 7–12 months, while 37.4% would never-
theless refer the patient to a board-certified urologist.
 21.9% of those physicians taking a definite position on 
this topic are convinced that reduction of PCa mortality 
cannot be achieved by PSA-based early PCa detection. In 
contrast, 35.5% of the colleagues would favour an explic-
it guideline recommendation of yearly PSA testing start-
ing at the age of 50 (45 for men at risk). 28.3% of the col-
leagues stated that their knowledge concerning PSA-
based early PCa detection was exclusively generated by 
continuing GP or IS education. The aptitude of a depart-
ment as a certified PCa centre is appreciated by almost all 
colleagues. It represents the main quality criterion for 
treatment recommendation and referral for 45.7% of 
physicians.
 Table 3 shows the impact of answers for selected indi-
cator items in dichotomised categories on the willingness 
of physicians to apply PSA-based early PCa detection. 
The following groups are most experienced in PSA-based 
early PCa detection: GPs and ISs working in hospitals, 
physicians who completed their medical training more 
than 10 years ago, physicians considering a reduction in 
PCa mortality by PSA-based early PCa detection possible 
or proven by evidence, physicians who recommend pros-
tatectomy or percutaneous radiotherapy for low-risk 
PCa, physicians favouring yearly PSA testing starting at 
the age of 50, and physicians stating that their knowledge 
concerning PSA-based early PCa detection was exclusive-
ly generated by continuing GP or IS education.
 The selected dichotomised indicator items were final-
ly included into a MLRA whose coefficient of determina-
tion was required to exceed 35% (Nagelkerke R 2  = 0.39). 
The following criteria had the highest independent im-
pact on the positive attitude of colleagues outside the uro-
logical field towards PSA-based early PCa detection: spe-
cialisation, physicians who use exclusively GP or IS edu-
cation, and physicians who recommend yearly PSA 
assessment after the age of 50 ( table 4 ). MLRA revealed a 
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Table 2.  Experience of participating physicians (n = 392) in PSA-based early PCa detection as a function of their specialisation and an-
swers on different indicator questions (items)







PSA-based early detection 




























































Age of stopping PSA-based early detection (item 5)
Until the age of 60
Until the age of 70
Until the age of 80
Until the age of 90









































Management of pathological PSA (item 7)
PSA monitoring after 2–4 weeks
Antibiotics, then PSA re-assessment
PSA monitoring after 3–6 months
PSA monitoring after 7–12 months
Urine culture























PSA re-assessment normal (item 8)
PSA re-assessment after 2–4 weeks
PSA re-assessment after 3–6 months
PSA re-assessment after 7–12 months

















PSA re-assessment pathological (item 9)
PSA re-assessment after 2–4 weeks
Antibiotics, then PSA re-assessment
PSA re-assessment after 3–6 months
PSA re-assessment after 7–12 months
Urine culture 










































   
   
   
   
   
   
   
   
   
   
   

























 PSA-based early PCa detection is still under debate. 
The effectiveness of population-based PSA screening for 
PCa could not be finally proven by the two large screening 
studies, the ERSPC  [2] and the PLCO trial  [3] , despite their 
different results. In the ERSPC, PCa-specific mortality was 
found to be reduced by 21% in the PSA-based early PCa 
detection group as compared to the control group after a 
mean follow-up of 11 years  [2] . This translates into a re-
duction of individual cancer-specific risk of mortality of 
about 3% without PSA-based early PCa detection to 2.4% 
with PSA-based early PCa detection. In conclusion, the 
results of this study suggest that 1,055 men have to par-
Table 2.  (continued)







PSA-based early detection 
experience (n = 75; 19.1%)





















PCa mortality reduction by PSA-based early detection (item 11)
Yes (evidence proof)












































Annual PSA test beginning at the age of 50 (45 for men at risk) (item 13)
Yes



















Personal contact with urologists
Numerous options



















Consequences of a certification as PCa centre (item 15)
Better quality of therapy
Poorer quality of treatment














Recommendation of treatment in a PCa centre (item 16)
Yes
No, on the contrary
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ticipate in PSA-based early PCa detection and 37 men have 
to undergo therapy in order to save one man’s life from 
PCa within the follow-up period  [2] . In another statistical 
analysis of this study accounting for contamination of the 
control group by PSA testing of men in this group not in-
dicated by the study protocol, a decrease in PCa mortality 
of 29% could be shown for PSA-based early PCa detection 
 [2] . These positive results were even outperformed by the 
‘Göteborg randomised population-based prostate-cancer 
screening trial’, in which PCa mortality could be reduced 
by 44% as compared to the control arm (1 life saved with-
in 12 men who underwent therapy of 293 men screened) 
Table 3.  Distribution of dichotomised response possibilities of selected items on the two options of item 1.3











GP (non-certified) or IS (office-based)






K: τ = 0.204 (p < 0.001)








K: τ = 0.120 (p = 0.017)
PCa mortality reduction by PSA-based early detection (item 11)







K: τ = 0.276 (p < 0.001)
Therapy recommendations for a 62-year-old man with low-risk PCa (item 12)
Brachytherapy, active surveillance, no answer






K: τ = 0.171 (p < 0.001)
Annual PSA test beginning at the age of 50 (45 in men at risk) (item 13)
No or no answer






K: τ = 0.417 (p < 0.001)








K: τ = 0.191 (p < 0.001)
 Selection of items and way of dichotomisation was carried out by using reasonable combinations according to the results of table 1. The extent of differ-
ence was tested by using Fisher’s exact test, the evaluation of concordance was tested by using the Kendall (τ) correlation coefficient.
Table 4.  MLRA created to test the independent impact of different dichotomised indicator questions on the willingness of GPs and ISs 
to apply PSA-based early PCa detection
Dichotomised items/indicator questions OR (95% CI) p Slope index
Specialisation (item 1)
GP (board-certified) or IS (working in hospitals) (reference: other options) 3.12 (1.66–5.89) <0.001 0.97
Time since specialisation (item 2)
≥11 years (reference: ≤10 years) 1.86 (0.99–3.49) 0.055 0.95
PCa mortality reduction by PSA-based early detection (item 11)
Yes or possible (reference: other options) 2.03 (1.07–3.88) 0.031 0.98
Therapy recommendations for a 62-year-old man with low-risk PCa (item 12)
Prostatectomy or percutaneous radiotherapy (reference: other options) 3.43 (1.51–7.81) 0.003 0.93
Annual PSA test beginning at the age of 50 (45 in men at risk) (item 13)
Yes or interval adjusted to PSA levels (reference: other options) 6.85 (3.61–12.98) <0.001 0.96
Knowledge acquisition on PSA-based early detection (item 14)
Only GP/IS training (reference: other options) 3.95 (1.67–9.33) 0.002 0.94
 A coefficient of determination exceeding 35% was required for inclusion of an indicator question into the MLRA.
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 [13] . Contamination by PSA testing within the control 
group was one major limitation of the PLCO trial. There-
fore, reduction in PCa mortality by PSA-based early PCa 
detection could not be demonstrated and cannot be ex-
pected even after prolongation of the follow-up period  [3] .
 Representative data for the use of PSA-based early PCa 
detection in Germany are lacking in the urological com-
munity as well as in the non-urological field. While urol-
ogists are expected to act consistently with the German S3 
guideline and findings of the recent literature in order to 
ensure their expertise  [1–6] , this cannot be deduced for 
GPs and ISs by implication. On the other hand, interna-
tional studies show that PSA-based early PCa detection is 
widely used by GPs and ISs  [7–10, 14–20] . Furthermore, 
there is no scientific evidence on which consequences are 
drawn by GPs and ISs based upon given PSA levels in 
combination with clinical findings. Available study data 
on this topic illustrate the heterogeneous role of GPs in 
population-based PSA screening for PCa in various coun-
tries  [7–10, 14–20] . A recently published study by van der 
Meer et al.  [21] , exploring the impact of ERSPC results on 
the implementation of population-based PCa screening 
by GPs in daily routine, clearly showed the consequences 
in the region of Rotterdam: (a) after publication of the 
ERSPC data, fewer PSA tests were performed by GPs in 
men  ≥ 60 years of age; (b) PSA levels of 4–10 ng/ml were 
controlled significantly less frequently; (c) significantly 
fewer patients with a PSA level >4 ng/ml were referred to 
a board-certified urologist. This possible development 
mentioned in (b) and (c) is not only questionable in terms 
of necessary professional prudence, but may also have le-
gal consequences as this can be declared as medical mal-
practice by committees of valuation experts of the medi-
cal associations in Germany  [22] .
 The results of our study constitute the first available data 
on how GPs and ISs use PSA testing as an instrument for 
early detection of PCa in Germany. It is shown that PSA-
based early PCa detection is performed by four out of five 
colleagues outside the urological field. Approximately 
three out of four physicians applying PSA-based early PCa 
detection would immediately refer patients with a patho-
logical PSA level to a board-certified urologist. In contrast, 
13% would re-assess the PSA level after 3–12 months them-
selves, which may be considered as arguable referring to the 
study mentioned above  [22] . Almost two thirds of physi-
cians involved in our study (62%) consider a decrease in 
PCa mortality by PSA-based early PCa detection possible, 
but claim more reliable evidence, which might be achieved 
by further studies. The following criteria were indepen-
dently associated with a positive attitude of non-urological 
physicians towards PSA-based early PCa detection: spe-
cialisation (application of early detection more frequent for 
GPs and ISs working in hospitals) (OR 3.12; p < 0.001), 
physicians who use exclusively GP or IS education (OR 
3.95; p  = 0.002), and physicians who recommend yearly 
PSA assessment after the age of 50 (OR 6.85; p < 0.001).
 When interpreting the results of our study, seven limi-
tations have to be considered: (1) Although evaluable ques-
tionnaires reached a sufficient number to ensure a robust 
statistical analysis, the return rate was only 65%. It seems 
possible that physicians with a thorough knowledge of the 
topic and highly interested in PSA-based early PCa detec-
tion were more motivated to complete the questionnaire. 
This may have resulted in limited representativeness. (2) 
GPs and ISs were contacted solely in the federal state of 
Brandenburg and in Berlin, but this should only minimal-
ly influence the translation of the study results for other 
areas of Germany. However, GPs and ISs might have a dif-
ferent approach to PSA-based early PCa detection in other 
countries with various health care systems, so that our re-
sults may only cautiously be extrapolated under these con-
ditions. (3) Furthermore, it has to be considered that the 
data presented here resulted from a survey as opposed to 
exact data acquisition of PSA testing in clinical routine. It 
remains unclear how many patients are screened by GPs 
and ISs in reality. (4) It was not differentiated whether GPs 
and ISs perform real population-based screening or a rath-
er opportunistic PSA-based early PCa detection. (5) No 
conclusions could be extracted from our study neither con-
cerning the type of counselling about advantages and dis-
advantages of PSA-based early PCa detection prior to PSA 
testing nor what kind of information sheets or similar ma-
terial is used by GPs  [23–25] . (6) Moreover, based on our 
study, we do not know how frequently GPs and ISs com-
bine PSA testing with digital rectal examination as required 
by the German interdisciplinary S3 guideline for early de-
tection of PCa  [1] . (7) Finally, only 39% of variances that 
motivated GPs and ISs working in hospitals to apply PSA-
based early PCa detection could be illustrated to our 
MLRA. This implicates that there must be a number of 
factors on top of those considered in our model that influ-
ence decision-making by GPs and ISs concerning PSA-
based early PCa detection. Despite these limitations, we 
believe that the results of this first German study analysing 
the application of PSA testing as a tool for early detection 
of PCa may shed some light on which knowledge and 
which motivation guide GPs and ISs in using it.
 In summary, about four out of five colleagues in the 
field of general and internal medicine perform early de-
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three out of four physicians would refer patients with 
pathological PSA levels immediately to a board-certified 
urologist for further diagnostics. Approximately 13% of 
colleagues outside the urological field may wait too long 
before re-evaluating increased PSA levels. The following 
criteria were independently associated with a positive at-
titude of non-urological physicians towards PSA-based 
early PCa detection: specialisation (application of early 
detection more frequent for GPs and ISs working in hos-
pitals), physicians who exclusively use GP or IS educa-
tion, and physicians who recommend yearly PSA assess-
ment after the age of 50. Specific educational activities for 
non-urological physicians active in fields of urological 
core capabilities should be guided by joint boards of the 
national associations of urology and general medicine.
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